Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias. Issue 2 (19th February 2022)

• Record Type: Journal Article
• Authors: Isotani, Yoshitaka; Amiya, Eisuke; Ishida, Junichi; Ishizuka, Masato; Hatano, Masaru; Nakanishi, Koki; Daimon, Masao; Komuro, Issei
• Is Part Of: Oxford medical case reports. Volume 2022:Issue 2(2022)
• Publication Date: 2022-02-19
• Subjects: Clinical medicine -- Case studies -- Periodicals; 616.09
• DOI: 10.1093/omcr/omac007
• Languages: English
• ISSNs: 2053-8855

Abstract

ABSTRACT: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening infiltrative disease in elderly patients. Atrial arrhythmias (AAr) are common in patients with ATTR-CM. However, AAr treatment in these patients is challenging. In this case, a patient diagnosed with wild-type ATTR-CM suffered atrial fibrillation (AF) for ~1 year, according to the data of his self-monitoring and regular electrocardiogram. This AF reverted to normal sinus rhythm a few months after the initiation of tafamidis without administering an antiarrhythmic drug. Tafamidis may be beneficial as alternative antiarrhythmic therapy in patients with ATTR-CM.